Table 1.
Prevalence of reported hypersensitivity reactions (HSRs) by patient demographic characteristics and by HSR phenotype among a total of 2,734,506 patients; 377,474 patients reported 580,456 HSRs*
| Total (n= 2,734,506) n (%)a |
Sexb,c
n (%)a |
Racial/ethnic groupd
n (%)a |
||||||
|---|---|---|---|---|---|---|---|---|
| Female (n=1,511,555) |
Male (n=1,222,649) |
Whitee
(n=1,814,521) |
Blackf
(n=156,892) |
Hispanicg
(n=171,071) |
Asianh
(n=94,332) |
Otheri
(n=47,028) |
||
| Patients with HSRs | 377,474 (13.8) | 265,539 (17.6) | 111,915 (9.2) | 292,564 (16.1) | 14,230 (9.1) | 13,828 (8.1) | 8,075 (8.6) | 4,178 (8.9) |
| Immediate HSR Phenotypes | 215,643 (7.9) | 154,536 (10.2) | 61,093 (5.0) | 165,619 (9.1) | 9,245 (5.9) | 7,577 (4.4) | 4,053 (4.3) | 2,272 (4.8) |
| Itching | 37,562 (1.4) | 28,395 (1.9) | 9,162 (0.7) | 28,164 (1.6) | 2,443 (1.6) | 1,793 (1.0) | 781 (0.8) | 461 (1.0) |
| Hives | 118,828 (4.3) | 85,984 (5.7) | 32,834 (2.7) | 91,446 (5.0) | 4,009 (2.6) | 3,476 (2.0) | 2,083 (2.2) | 1,160 (2.5) |
| Respiratory reactions | 23,204 (0.8) | 17,249 (1.1) | 5,954 (0.5) | 18,245 (1.0) | 1,047 (0.7) | 909 (0.5) | 438 (0.5) | 239 (0.5) |
| Angioedema | 36,217 (1.3) | 26,043 (1.7) | 10,173 (0.8) | 27,583 (1.5) | 2,131 (1.4) | 1,638 (1.0) | 747 (0.8) | 438 (0.9) |
| Anaphylaxis | 29,486 (1.1) | 20,620 (1.4) | 8,865 (0.7) | 23,779 (1.3) | 995 (0.6) | 910 (0.5) | 423 (0.4) | 307 (0.7) |
| Delayed HSR Phenotypes | 211,761 (7.7) | 149,013 (9.9) | 62,727 (5.1) | 163,237 (9.0) | 6,578 (4.2) | 7,896 (4.6) | 4,845 (5.1) | 2,357 (5.0) |
| Rash | 210,162 (7.7) | 148,090 (9.8) | 62,050 (5.1) | 162,033 (8.9) | 6,500 (4.1) | 7,853 (4.6) | 4,784 (5.1) | 2,341 (5.0) |
| Fixed drug eruption | 78 (0.003) | 36 (0.002) | 42 (0.003) | 51 (0.003) | 6 (0.004) | 3 (0.002) | 7 (0.007) | 1 (0.002) |
| Erythema nodosum | 77 (0.003) | 72 (0.005) | 5 (0.0) | 60 (0.003) | 2 (0.001) | 2 (0.001) | 2 (0.002) | 0 |
| Serum sickness | 497 (0.02) | 345 (0.02) | 152 (0.01) | 401 (0.02) | 9 (0.01) | 10 (0.01) | 6 (0.01) | 4 (0.01) |
| Pneumonitis | 96 (0.004) | 65 (0.004) | 31 (0.003) | 86 (0.005) | 0 | 0 | 2 (0.002) | 1 (0.002) |
| AIN | 381 (0.01) | 177 (0.01) | 204 (0.02) | 295 (0.02) | 34 (0.02) | 11 (0.01) | 9 (0.01) | 7 (0.01) |
| SCAR | 1,122 (0.04) | 674 (0.04) | 448 (0.04) | 824 (0.05) | 57 (0.04) | 37 (0.02) | 50 (0.05) | 15 (0.03) |
| Both Immediate and Delayed HSR Phenotypes | 49,930 (1.8) | 38,772 (2.5) | 11,158 (0.9) | 40,193 (2.2) | 1,764 (1.1) | 1,821 (1.1) | 911 (1.0) | 499 (1.1) |
AIN = acute interstitial nephritis; PEAR = Partners Enterprise-wide Allergy Repository; SCAR = severe cutaneous adverse reaction
Percentage is prevalence of HSR among the entire population in PEAR; columns may add up to greater than 100% as patients may have had multiple HSR by HSR group
Denominator used is patients in PEAR that are part of group (i.e., by column)
Sex information for patients with an HSR was missing for 302 patients
All HSRs comparing females and males were significantly (p<0.05) more prevalent among females than males, except for AIN, which was significantly more prevalent (p<0.05) among males than females, and fixed drug eruption (p>0.05)
Race information for patients with an HSR was missing (e.g., unknown, refused) for 44,599 patients
White patients had a significantly (p<0.05) higher prevalence of all HSRs, compared to the rest of the PEAR population
Black patients had a significantly (p<0.05) higher prevalence of itching, compared to the rest of the PEAR population; Black patients had a significantly (p<0.05) lower prevalence of HSRs; immediate HSRs, hives, respiratory reactions, anaphylaxis; delayed HSRs, rash, serum sickness, SCAR; and both immediate and delayed HSRs, compared to the rest of the PEAR population
Hispanic patients had a significantly (p<0.05) lower prevalence of HSRs; immediate HSRs, itching, hives, respiratory reactions, angioedema, anaphylaxis; delayed HSRs, rash, serum sickness, AIN, SCAR; and both immediate and delayed HSRs, compared to the rest of the PEAR population
Asian patients had a significantly (p<0.05) higher prevalence of fixed drug eruption, compared to the rest of the PEAR population; Asian patients had a significantly (p<0.05) lower prevalence of HSRs; immediate HSRs, itching, hives, respiratory reactions, angioedema, anaphylaxis; delayed HSRs, rash, serum sickness, SCAR; and both immediate and delayed HSRs, compared to the rest of the PEAR population
Other patients had a significantly (p<0.05) lower prevalence of HSRs; immediate HSRs, itching, hives, respiratory reactions, angioedema, anaphylaxis; delayed HSRs, rash; and both immediate and delayed HSRs, compared to the rest of the PEAR population